Skip to main content Back to Top
Advertisement

2/7/2020

Tacrolimus Extended-Release Capsules and Tablets

Products Affected - Description

    • Astagraf XL oral extended release capsule, Astellas, 0.5 mg, 30 count, NDC 00469-0647-73
    • Astagraf XL oral extended release capsule, Astellas, 1 mg, 30 count, NDC 00469-0677-73
    • Astagraf XL oral extended release capsule, Astellas, 5 mg, 30 count, NDC 00469-0687-73

Reason for the Shortage

    • Astellas has Astagraf XL capsules on allocation.

Available Products

    • Envarsus XR oral extended release tablet, Veloxis, 0.75 mg, 30 count, NDC 6899-3075-03
    • Envarsus XR oral extended release tablet, Veloxis, 0.75 mg, 100 count, NDC 6899-3075-01
    • Envarsus XR oral extended release tablet, Veloxis, 1 mg, 30 count, NDC 6899-3010-03
    • Envarsus XR oral extended release tablet, Veloxis, 1 mg, 100 count, NDC 6899-3010-01
    • Envarsus XR oral extended release tablet, Veloxis, 4 mg, 30 count, NDC 6899-3040-03
    • Envarsus XR oral extended release tablet, Veloxis, 4 mg, 100 count, NDC 6899-3040-01

Estimated Resupply Dates

    • Astellas has Astagraf XL available on allocation.

Updated

Updated February 7, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created September 18, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins